Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...
In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant ...
In the U.S., atrial fibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the ...
The ECDP also highlights that SGLT inhibitors can be started at any time during the pathway, including throughout hospitalization regardless of left ventricular ejection fraction. Other topics ...
The ejection fraction in these patients was less than ... associated with excess extracellular fluid, it is important to monitor patients on diuretic therapy to prevent serious, potentially ...
The study also showed that exercise was safe even for patients at high risk—those with ischemic cardiomyopathy with ejection fractions of ... First, they can monitor your vitals to make sure ...
These findings indicate that ultrasound can effectively monitor the gastrointestinal structure and ... of the two groups of subjects and the B-type natriuretic peptide (BNP), cardiac ejection fraction ...
Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR).
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major health concern. Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to ...
Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR), according to a study ...